Insider transactions

Peter S Ringrose

CIK 1199298 · last filed 2019-05-02

Peter S Ringrose is a corporate insider who has filed 20 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for TBPH, was dated May 2, 2019. 6 SEC filings were submitted jointly with Innoviva, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$0
Companies
3
Total Filings
20
Lifetime Open-Market Net
$0

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

RIGL price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O BRISTOL MYERS SQUIBB CO
345 PARK AVE
NEW YORK, NY 10164
Related Filers
Innoviva, Inc. — 6 joint filings, latest 2014-05-27
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Theravance Biopharma, Inc. (TBPH) Delisted Director 37,999 $17.03 $647.1K $0 5 2019-05-02
RIGL Director — $49.91 — $0 11 2018-05-18
Innoviva, Inc. (THRX) Delisted Director 30,000 $4.06 $121.8K $0 4 2013-04-26

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-05-02 Theravance Biopharma, Inc. (TBPH) Delisted Grant (A) +8,385 $0 EDGAR
2018-05-18 RIGL Grant (A) — $0 EDGAR
2018-05-03 Theravance Biopharma, Inc. (TBPH) Delisted Grant (A) +8,186 $0 EDGAR
2017-05-18 Theravance Biopharma, Inc. (TBPH) Delisted Grant (A) +6,000 $0 EDGAR
2017-05-12 RIGL Grant (A) — $0 EDGAR
2016-05-12 RIGL Grant (A) — $0 EDGAR
2016-05-05 Theravance Biopharma, Inc. (TBPH) Delisted Grant (A) +6,000 $0 EDGAR
2015-05-14 RIGL Grant (A) — $0 EDGAR
2015-04-24 Theravance Biopharma, Inc. (TBPH) Delisted Grant (A) +6,000 $0 EDGAR
2013-05-28 RIGL Grant (A) — $0 EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.